Morgan Stanley’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Morgan Stanley’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,000	Closed	-$860	–	7950
2023 Q3	$860	Hold	2,000	–	–	﹤0.01%	7254
2023 Q2	$2.54K	Hold	2,000	–	–	﹤0.01%	7140
2023 Q1	$2.8K	Sell	2,000 -142	-7%	-$339	﹤0.01%	7177
2022 Q4	$8.03K	Sell	2,142 -9,377	-81%	-$34.2K	﹤0.01%	7012
2022 Q3	$55K	Sell	11,519 -4,147	-26%	-$31.7K	﹤0.01%	6369
2022 Q2	$145K	Buy	15,666 +4,554	+41%	+$33.3K	﹤0.01%	6066
2022 Q1	$70K	Sell	11,112 -967	-8%	-$7.31K	﹤0.01%	6530
2021 Q4	$105K	Buy	12,079 +5,730	+90%	+$57.2K	﹤0.01%	6413
2021 Q3	$78K	Sell	6,349 -1,539	-20%	-$22.3K	﹤0.01%	6505
2021 Q2	$69K	Buy	+7,888	New	+$94.2K	﹤0.01%	6523

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Morgan Stanley's IMPL Position: Q4 2023 in Review

Morgan Stanley sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 2,000 shares — an estimated $860 sold.

Morgan Stanley first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $145K in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Morgan Stanley reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Morgan Stanley sold 2,000 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $860.
Morgan Stanley first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Morgan Stanley's Impel Pharmaceuticals Inc. Common Stock position peaked at $145K in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.